SOL-GEL TECHN. IS-10 Total Assets
SOL-GEL TECHN. IS-10 total assets. Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) holds total assets worth €53.76 Million EUR (≈ $62.85 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SOL-GEL TECHN. IS-10 stock valuation for the company's overall valuation and market capitalisation.
Total Assets of SOL-GEL TECHN. IS-10 (2021–2025)
Total assets of SOL-GEL TECHN. IS-10 from 2021 to 2025. This chart illustrates how SOL-GEL TECHN. IS-10's total assets have evolved over time, based on quarterly financial data. See SOL-GEL TECHN. IS-10 stock quote for real-time trading data and today's change.
SOL-GEL TECHN. IS-10 - Asset Composition Analysis
SOL-GEL TECHN. IS-10 Total Assets Breakdown (December 2025)
SOL-GEL TECHN. IS-10 total assets breakdown as of December 2025. SOL-GEL TECHN. IS-10's total assets of €53.76 Million consist of 90.2% current assets and 9.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 36.9% |
| Accounts Receivable | €1.97 Million | 6.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SOL-GEL TECHN. IS-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 4SG working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SOL-GEL TECHN. IS-10's current assets represent 90.2% of total assets in 2025, an increase from 82.5% in 2021.
- Cash Position: Cash and equivalents constituted 36.9% of total assets in 2025, up from 29.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
SOL-GEL TECHN. IS-10 Competitors by Total Assets
Key competitors of SOL-GEL TECHN. IS-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
SOL-GEL TECHN. IS-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.37 | 7.32 | 5.81 |
| Quick Ratio | 10.37 | 7.32 | 5.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €46.15 Million | €31.31 Million | €31.42 Million |
SOL-GEL TECHN. IS-10 - Advanced Valuation Insights
This section examines the relationship between SOL-GEL TECHN. IS-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.59 |
| Latest Market Cap to Assets Ratio | 6.29 |
| Asset Growth Rate (YoY) | -16.5% |
| Total Assets | €29.92 Million |
| Market Capitalization | $188.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SOL-GEL TECHN. IS-10's assets at a significant premium (6.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: SOL-GEL TECHN. IS-10's assets decreased by 16.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual total assets of SOL-GEL TECHN. IS-10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €29.92 Million ≈ $34.98 Million |
-16.54% |
| 2024-12-31 | €35.85 Million ≈ $41.91 Million |
-20.85% |
| 2023-12-31 | €45.29 Million ≈ $52.95 Million |
-2.88% |
| 2022-12-31 | €46.63 Million ≈ $54.51 Million |
-32.61% |
| 2021-12-31 | €69.19 Million ≈ $80.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more